New drugs battle heart plaque in Pre-Diabetes patients
NCT ID NCT07254572
Summary
This study aims to find out if newer diabetes medications (semaglutide or dapagliflozin) are better than the standard drug metformin at slowing or reversing the buildup of fatty plaque in the heart's arteries of people who have both coronary artery disease and pre-diabetes. It will enroll 300 adults and use special heart scans to measure changes in plaque over two years. The goal is to see which treatment best controls the progression of heart disease in this at-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Cardiology, Department of Coronary Artery and Structural Heart Diseases
RECRUITINGWarsaw, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.